Eli Lilly’s dulaglutide doses show blood control and weight benefits at Phase 2
pharmafile | June 25, 2018 | News story | Research and Development, Sales and Marketing | Eli Lilly, Trulicity, diabetes, pharma
Eli Lilly has announced new data on its once-weekly, injectable glucagon-like peptide Trulicity (dulaglutide 1.5mg) and investigational 3.0 and 4.5mg doses of dulaglutide, revealing that all three provided “significantly better blood sugar control with weight benefits” in the treatment of type 2 diabetes compared to placebo.
Specifically, after 18 weeks of continuous treatment, all three doses generated superior reductions in A1C from baseline from baseline: the 4.5mg dose saw reductions of 1.5%, 1.47% for the 3.0mg dose, and 1.24% for the approved 1.5mg dose. In addition, the aforementioned weight loss benefits were recorded as a loss of 4.4kg in the 4.5mg group, 4.2kg in the 3.0mg group, and 1.6kg with the 1.5mg dose.
Lilly stated that it would be presenting the findings of the Phase 2 study at the American Diabetes Association’s (ADA) 78th Scientific Sessions in Orlando.
“The progressive nature of type 2 diabetes often means that people must continue advancing treatment throughout the natural development of their condition,” said Dr Juan P Frias, President and Principal Investigator, National Research Institute. “Trulicity is an effective, once-weekly GLP-1 RA option, and this study of investigational doses shows potential in providing further improved blood glucose control without changing treatment.”
Dr Brad Woodward, Senior Medical Director at Lilly Diabetes, added: “Once-weekly Trulicity offers people with type 2 diabetes a significant opportunity to reach their blood sugar goals and achieve low hypoglycemia rates with the potential for weight loss. We’re always looking for opportunities to provide meaningful choices for people with diabetes, which is why we’re studying investigational dulaglutide doses beyond the two effective Trulicity doses already approved.”
Matt Fellows
Related Content
Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity
Eli Lilly has announced positive topline results from its SURMOUNT-OSA phase 3 trials which demonstrated …
CHMP recommends Novo Nordisk’s Awiqli for diabetes treatment
Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for …
Roche shares data on novel solution for continuous glucose monitoring
Roche has shared the latest data on its novel solution for continuous glucose monitoring (CGM), …
